Skip to main content
SpringerLink
Log in

Hyperhomocysteinemia, Vascular Function and Atherosclerosis: Effects of Vitamins

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Homocysteine is a metabolic product of methyl group donation by the amino acid methionine. Moderate elevation of plasma homocysteine (>15 μM) is most commonly caused by B-vitamin deficiencies, especially folic acid, B6 and B12. Genetic factors, certain drugs and renal impairment may also contribute. Homocysteine has several potentially deleterious vascular actions. These include increased oxidant stress, impaired endothelial function, stimulation of mitogenesis, and induction of thrombosis. Homocysteine also appears to increase arterial pressure. In humans, experimental induction of hyperhomocysteinemia by methionine loading rapidly causes profound impairment of endothelium-dependent dilatation in both resistance and conduit arteries. This endothelial dysfunction can be reversed by administration of antioxidants. Epidemiological evidence suggests that homocysteine acts as an independent risk factor for atherosclerosis, thrombosis and hypertension. Prospective studies have shown that elevated plasma homocysteine concentrations in the top quintile of the population (>12 μM) increase risk of cardiovascular disease by about 2-fold. There are currently no data available from randomized, controlled trials of the effects of lowering plasma homocysteine on atherothrombotic events. Nonetheless, it would seem appropriate to screen for and treat hyperhomocysteinemia in individuals with progressive or unexplained atherosclerosis. Folic acid and vitamins B6 and B12 are the mainstay of therapy. Treatment of moderately elevated plasma homocysteine in patients without atherosclerosis should be deferred until the completion of randomized outcome trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mudd SH, Levy HL, Scovby F. Disorders of transulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th ed. New York: McGraw-Hill, 1989:693–734.

    Google Scholar 

  2. McCully KS.Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis.AmJ Pathol 1969;56:111–128.

    Google Scholar 

  3. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th ed. New York: McGraw-Hill, 1989:2049–2064.

    Google Scholar 

  4. Stampfer MJ, Malinow MR, Willett MC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–881.

    Google Scholar 

  5. Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: Results from the third national health and nutrition examination survey. Am J Clin Nutr 1999;69:482–489.

    Google Scholar 

  6. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora J. Thermolabile defect of methylene-tetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463–1469.

    Google Scholar 

  7. Rozen R. Genetic predisposition to hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997;78:523–526.

    Google Scholar 

  8. Morita H, Kurihara H, Tsubaki S, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998;18:1465–1469.

    Google Scholar 

  9. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 1998;98:2520–2526.

    Google Scholar 

  10. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and Bvitamins: The Atherosclerosis risk in communities (ARIC) study. Circulation 1998;98:204–210.

    Google Scholar 

  11. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJ, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 1998;141:161–166.

    Google Scholar 

  12. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–2698.

    Google Scholar 

  13. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85–89.

    Google Scholar 

  14. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The hordaland homocysteine study.AmJ Clin Nutr 1998;67:263–270.

    Google Scholar 

  15. Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994;124:1934–1941.

    Google Scholar 

  16. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993;13:1327–1333.

    Google Scholar 

  17. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909–1916.

    Google Scholar 

  18. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906–1914.

    Google Scholar 

  19. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982;16:490–493.

    Google Scholar 

  20. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydyl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193–10197.

    Google Scholar 

  21. Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998;273:9987–9993.

    Google Scholar 

  22. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophagederived tissue factor activity in rats.FASEBJ 1997;11:1157–1168.

    Google Scholar 

  23. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteineinduced endothelial cell injury in vivo: A model for the study of vascular injury. Thromb Res 1980;18:113–121.

    Google Scholar 

  24. De Groot PG, Willems C, Boers GHJ, et al. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983;13:405–410.

    Google Scholar 

  25. Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997;272:25380–25385.

    Google Scholar 

  26. Dudman NPB, Temple SE, Guo XW, Fu WY, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circ Res 1999;84:409–416.

    Google Scholar 

  27. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308–318.

    Google Scholar 

  28. McCully KS, Ragsdale BD. Production of arteriosclerosis by homocysteinemia. Am J Pathol 1970;61:1–11.

    Google Scholar 

  29. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteineinduced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731–741.

    Google Scholar 

  30. Hladovec J. Experimental homocysteinemia, endothelial lesions, and thrombosis. Blood Vessels 1979;18:11–20.

    Google Scholar 

  31. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995;91:1161–1174.

    Google Scholar 

  32. Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996;98:24–29.

    Google Scholar 

  33. Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai MB, Faraci FM, Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol 1997;17:2930–2934.

    Google Scholar 

  34. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854–858.

    Google Scholar 

  35. Takawol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997;95:1119–1121.

    Google Scholar 

  36. Izzo MR, Feldman MD, Wu CC, et al. Lowering plasma homocysteine improves brachial artery vasoreactivity in patients with coronary artery disease. Circulation 1995;92(Suppl I):I-708 (Abstract).

    Google Scholar 

  37. Kanani PM, Sinkey CA, Browning RL, Alleman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; (in Press).

  38. Bellamy MF, McDowell IF, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848–1852.

    Google Scholar 

  39. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36–37.

    Google Scholar 

  40. Haynes WG, Sinkey CA, Kanani P. Acute methionine loading produces endothelial dysfunction in humans. J Invest Med 1997;45:210A.

    Google Scholar 

  41. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inemia: Restoration by folic acid. Clin Sci 1999;96:235–239.

    Google Scholar 

  42. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1993;77:1370–1376.

    Google Scholar 

  43. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098–10103.

    Google Scholar 

  44. Emsley AM, Jeremy JY, Gomes GN, Angelini GD, Plane F. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Brit J Pharmacol 1999;126:1034–1040.

    Google Scholar 

  45. Upchurch GR, Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012–17017.

    Google Scholar 

  46. Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology 1997;123:33–40.

    Google Scholar 

  47. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Comm 1998;251:669–676.

    Google Scholar 

  48. Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998;136:169–173.

    Google Scholar 

  49. Dalton ML, Gadson PF, Jr, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: Production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997;11:703–711.

    Google Scholar 

  50. Southern FN, Cruz N, Fink LM, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 1998;28:909–918.

    Google Scholar 

  51. Charpiot P, Bescond A, Augier T, et al. Hyperhomocysteinemia induces elastolysis in minipig arteries: Structural consequences, arterial site specificity and effect of captoprilhydrochlorothiazide. Matrix Biol 1998;17:559–574.

    Google Scholar 

  52. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745–1749.

    Google Scholar 

  53. Fiorina P, Lanfredini M, Montanari A, et al. Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Am J Hypertens 1998;11:1100–1107.

    Google Scholar 

  54. Boushey CJ, Beresford SAA, Omenn GS, Molutsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049–1057.

    Google Scholar 

  55. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775–1781.

    Google Scholar 

  56. Montalescot G, Ankri A, Chadefaux-Vekemans B, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol 1997;60:295–300.

    Google Scholar 

  57. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly:TheRotterdam study. Arch InternMed1999;159:38–44.

    Google Scholar 

  58. Ridker PM, Buring JE, Manson JE, Hennekens CH. A prospective study of total homocysteine and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;19(Suppl):I–810 (Abstract).

    Google Scholar 

  59. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–236.

    Google Scholar 

  60. Meleady R, Lindgren A, Boers GHJ, et al. Plasma homocysteine as a prognostic risk factor for vascular disease. Eur Heart J 1998;19(Suppl):8 (Abstract).

    Google Scholar 

  61. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895–1901.

    Google Scholar 

  62. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997;11:217–223.

    Google Scholar 

  63. Taylor LM, Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999;29:8–19.

    Google Scholar 

  64. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101–2106.

    Google Scholar 

  65. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosis. Lancet 1996;348:1120–1124.

    Google Scholar 

  66. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777–1782.

    Google Scholar 

  67. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 1997;17:2554–2558.

    Google Scholar 

  68. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998;97:138–141.

    Google Scholar 

  69. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia. Lancet 1998;351:263.

    Google Scholar 

  70. Daly L, Meleady R, Graham I. Fasting or post-methionine load homocysteine: Which should be measured in relation to vascular risk? Ir J Med Sci 1995;164(Suppl 15):6 (Abstract).

    Google Scholar 

  71. van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996;16:165–171.

    Google Scholar 

  72. van der Griend R, Haas FJ, Duran M, Biesma DH, Meuwissen OJ, Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998;132:67–72.

    Google Scholar 

  73. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Metaanalysis of randomised trials. BMJ 1998;316:894–898.

    Google Scholar 

  74. Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997;127:1089–1092.

    Google Scholar 

  75. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009–1015.

    Google Scholar 

  76. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and homocysteine concentrations. N Engl J Med 1999;340:1449–1454.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Cardiovascular Diseases and Clinical Pharmacology, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, 52242-1081, USA

    William G. Haynes

Authors
  1. William G. Haynes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haynes, W.G. Hyperhomocysteinemia, Vascular Function and Atherosclerosis: Effects of Vitamins. Cardiovasc Drugs Ther 16, 391–399 (2002). https://doi.org/10.1023/A:1022130217463

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022130217463

Search

Navigation